RNLX Renalytix Plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RNLX

Price (delayed)

$0.7046

Market cap

$35.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.9

Enterprise value

$38.07M

renalytix ai plc (lse aim: renx) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. ...

Highlights
Renalytix's debt has decreased by 30% YoY and by 20% QoQ
The EPS has grown by 20% YoY and by 10% from the previous quarter
RNLX's equity has dropped by 190% year-on-year
The gross profit has dropped by 85% year-on-year and by 62% since the previous quarter
Sector: Healthcare
Industry: Health Information Services
Website: https://renalytixai.com/
Peers: PGY PHR PHUN

Key stats

What are the main financial stats of RNLX
Market
Shares outstanding
49.97M
Market cap
$35.21M
Enterprise value
$38.07M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
14.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.8
Earnings
Revenue
$2.41M
EBIT
-$41.84M
EBITDA
-$41.25M
Free cash flow
-$36.16M
Per share
EPS
-$0.9
Free cash flow per share
-$0.74
Book value per share
-$0.16
Revenue per share
$0.05
TBVPS
$0.23
Balance sheet
Total assets
$11.28M
Total liabilities
$19.23M
Debt
$8.48M
Equity
-$7.96M
Working capital
-$5.67M
Liquidity
Debt to equity
-1.07
Current ratio
0.59
Quick ratio
0.5
Net debt/EBITDA
-0.07
Margins
EBITDA margin
-1,711.5%
Gross margin
6.3%
Net margin
-1,736.5%
Operating margin
-1,592.6%
Efficiency
Return on assets
-165.3%
Return on equity
-1,071.9%
Return on invested capital
-2,426.7%
Return on capital employed
N/A
Return on sales
-1,736.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RNLX stock price

How has the Renalytix stock price performed over time
Intraday
-7.29%
1 week
11.84%
1 month
-12.69%
1 year
-68.68%
YTD
80.67%
QTD
-18.07%

Financial performance

How have Renalytix's revenue and profit performed over time
Revenue
$2.41M
Gross profit
$152,000
Operating income
-$38.38M
Net income
-$41.85M
Gross margin
6.3%
Net margin
-1,736.5%
The gross profit has dropped by 85% year-on-year and by 62% since the previous quarter
RNLX's gross margin has dropped by 76% year-on-year and by 55% since the previous quarter
Renalytix's net margin has shrunk by 56% YoY and by 15% QoQ
RNLX's revenue is down by 37% year-on-year and by 17% since the previous quarter

Growth

What is Renalytix's growth rate over time

Valuation

What is Renalytix stock price valuation
P/E
N/A
P/B
N/A
P/S
14.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.8
The EPS has grown by 20% YoY and by 10% from the previous quarter
RNLX's equity has dropped by 190% year-on-year
The price to sales (P/S) is 38% lower than the last 4 quarters average of 24.3
RNLX's revenue is down by 37% year-on-year and by 17% since the previous quarter

Efficiency

How efficient is Renalytix business performance
Renalytix's return on invested capital has shrunk by 139% YoY and by 58% QoQ
The return on equity has dropped by 99% since the previous quarter
RNLX's ROA has shrunk by 60% YoY and by 14% QoQ
The ROS has plunged by 56% YoY and by 15% from the previous quarter

Dividends

What is RNLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNLX.

Financial health

How did Renalytix financials performed over time
The total assets is 41% smaller than the total liabilities
RNLX's quick ratio has dropped by 71% year-on-year and by 49% since the previous quarter
The company's current ratio has shrunk by 68% YoY and by 46% QoQ
RNLX's equity has dropped by 190% year-on-year
RNLX's debt to equity has dropped by 178% year-on-year but it has surged by 85% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.